» Articles » PMID: 15328159

Distinct Homeostatic Requirements of CD4+ and CD4- Subsets of Valpha24-invariant Natural Killer T Cells in Humans

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Aug 26
PMID 15328159
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

CD1d-restricted Valpha24-invariant natural killer T cells (iNKTs) are important in immunoregulation. CD4(+) and CD4(-) iNKTs develop with similar frequencies in murine thymus and depend on interleukin-15 (IL-15) in periphery. However, homeostatic requirements of iNKTs have not been analyzed in humans. We evaluated thymic production, peripheral dynamics, and functional maturation of human iNKTs. CD4(+) subset comprises 90% of iNKTs in mature thymocytes and cord blood (CB) but only 40% in adult blood. Using T-cell receptor excision circle (TREC) analysis, we directly measured in vivo replicative history of CD4(+) and CD4(-) iNKT cells. Compared to CD4(+), CD4(-) iNKTs contain fewer TRECs, express higher levels of IL-2Rbeta, and proliferate with higher rate in response to IL-15. In contrast, CD4(+) cells express higher levels of IL-7Ralpha and better respond to IL-7. Neither thymic nor CB iNKTs are able to produce cytokines unless they are induced to proliferate. Therefore, unlike in the mouse, human CD4(+) iNKTs are mainly supported by thymic output and limited peripheral expansion, whereas CD4(-) cells undergo extensive peripheral expansion, and both subsets develop their functions in periphery. These findings reveal important differences in homeostatic requirements and functional maturation between murine and human iNKTs that are to be considered for clinical purposes.

Citing Articles

T Cell Development: From T-Lineage Specification to Intrathymic Maturation.

Golzari-Sorkheh M, Yoganathan K, Chen E, Singh J, Zuniga-Pflucker J Adv Exp Med Biol. 2025; 1471:81-137.

PMID: 40067585 DOI: 10.1007/978-3-031-77921-3_4.


Thymic development of human natural killer T cells: recent advances and implications for immunotherapy.

Pellicci D, Tavakolinia N, Perriman L, Berzins S, Menne C Front Immunol. 2024; 15:1441634.

PMID: 39267746 PMC: 11390520. DOI: 10.3389/fimmu.2024.1441634.


Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.

Zappa E, Vitali A, Anders K, Molenaar J, Wienke J, Kunkele A Eur J Cancer. 2023; 194:113347.

PMID: 37832507 PMC: 10695178. DOI: 10.1016/j.ejca.2023.113347.


Aging unconventionally: γδ T cells, iNKT cells, and MAIT cells in aging.

Kurioka A, Klenerman P Semin Immunol. 2023; 69:101816.

PMID: 37536148 PMC: 10804939. DOI: 10.1016/j.smim.2023.101816.


Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.

Courtney A, Tian G, Metelitsa L Blood. 2022; 141(8):869-876.

PMID: 36347021 PMC: 10023720. DOI: 10.1182/blood.2022016201.